S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
ACB   3.80 (+5.27%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
ACB   3.80 (+5.27%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Guardant Health Stock Price, News & Analysis (NASDAQ:GH)

$67.46
+2.44 (+3.75 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$64.79
Now: $67.46
$67.86
50-Day Range
$60.29
MA: $72.84
$94.73
52-Week Range
$31.01
Now: $67.46
$112.21
Volume649,564 shs
Average Volume1.09 million shs
Market Capitalization$6.27 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone855-698-8887

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.64 million
Book Value$5.63 per share

Profitability

Net Income$-85,060,000.00

Miscellaneous

Employees454
Market Cap$6.27 billion
Next Earnings Date11/18/2019 (Estimated)
OptionableNot Optionable

Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.


Guardant Health (NASDAQ:GH) Frequently Asked Questions

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

How were Guardant Health's earnings last quarter?

Guardant Health Inc (NASDAQ:GH) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.21. The business earned $53.98 million during the quarter, compared to the consensus estimate of $35.97 million. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The firm's revenue was up 178.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.75) EPS. View Guardant Health's Earnings History.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release their next quarterly earnings announcement on Monday, November 18th 2019. View Earnings Estimates for Guardant Health.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180-190 million, compared to the consensus revenue estimate of $148.52 million.

What price target have analysts set for GH?

6 equities research analysts have issued 1-year target prices for Guardant Health's stock. Their predictions range from $84.00 to $135.00. On average, they expect Guardant Health's stock price to reach $113.50 in the next twelve months. This suggests a possible upside of 68.2% from the stock's current price. View Analyst Price Targets for Guardant Health.

What is the consensus analysts' recommendation for Guardant Health?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Guardant Health.

Has Guardant Health been receiving favorable news coverage?

News coverage about GH stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Guardant Health earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Guardant Health.

Are investors shorting Guardant Health?

Guardant Health saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 3,380,000 shares, an increase of 25.7% from the August 30th total of 2,690,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 2.8 days. Approximately 8.0% of the shares of the company are short sold. View Guardant Health's Current Options Chain.

Who are some of Guardant Health's key competitors?

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include Twilio (TWLO), Okta (OKTA), Trade Desk (TTD), Shopify (SHOP), NVIDIA (NVDA), Square (SQ), Arista Networks (ANET), Teladoc Health (TDOC), Alibaba Group (BABA) and Canopy Growth (CGC).

Who are Guardant Health's key executives?

Guardant Health's management team includes the folowing people:
  • Mr. AmirAli Talasaz, Chairman, Pres & COO (Age 40)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 40)
  • Mr. Michael J. Wiley, Chief Legal Officer (Age 44)
  • Mr. Derek A. Bertocci, Chief Financial Officer (Age 65)
  • Dr. Richard B. Lanman, Chief Medical Officer (Age 64)

When did Guardant Health IPO?

(GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.04%), Scott & Selber Inc. (0.02%), SeaCrest Wealth Management LLC (0.01%) and Capital Investment Advisory Services LLC (0.00%). Company insiders that own Guardant Health stock include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman and Vision Fund (Aiv M1) Softbank. View Institutional Ownership Trends for Guardant Health.

Which major investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including Capital Investment Advisory Services LLC. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman and Vision Fund (Aiv M1) Softbank. View Insider Buying and Selling for Guardant Health.

Which major investors are buying Guardant Health stock?

GH stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Scott & Selber Inc. and SeaCrest Wealth Management LLC. View Insider Buying and Selling for Guardant Health.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $67.46.

How big of a company is Guardant Health?

Guardant Health has a market capitalization of $6.27 billion and generates $90.64 million in revenue each year. The company earns $-85,060,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Guardant Health employs 454 workers across the globe.View Additional Information About Guardant Health.

What is Guardant Health's official website?

The official website for Guardant Health is http://www.guardanthealth.com/.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.


MarketBeat Community Rating for Guardant Health (NASDAQ GH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Guardant Health and other stocks. Vote "Outperform" if you believe GH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel